Journal for ImmunoTherapy of Cancer (Nov 2020)
613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)
Abstract
No abstracts available.